Leucomax (molgramostim)
/ Merck (MSD)
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 24, 2026
A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden
(clinicaltrials.gov)
- P2 | N=60 | Not yet recruiting | Sponsor: University of Washington
New P2 trial • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer
1 to 1
Of
1
Go to page
1